Mark Brooker
-
Now available: proceedings of the 10th WFH Global Forum
The Proceedings of the 10th WFH Global Forum on Research and Treatment Products for Bleeding Disorders are now available online. The 10th WFH Global Forum—held...
-
FDA approves Hemlibra for treatment of hemophilia A with inhibitors
Roche has announced that the U.S.A Food and Drug Administration (FDA) has approved Hemlibra (emicizumab-kxwh) for the treatment of hemophilia A with inhibitors. This approval...
-
WFH STATEMENT on SIPPET Study Results
The results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were published May 26, 2016 in the New England Journal of Medicine....
-
SIPPET study results published in New England Journal of Medicine
May, 2016 – The results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were published today in the New England Journal of...
-
EMA committee completes review of Kogenate Bayer/Helixate NexGen studies
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has completed a review of data examining the risk of inhibitors associated with...
-
Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders
Access to safe and effective treatment products continues to improve each year due to the tireless advocacy from the global bleeding disorders community. This strategic priority...
-
A global snapshot of our community: The 2014 Annual Global Survey
The World Federation of Hemophilia (WFH) has begun collecting data from the national member organizations (NMOs) for the 2014 Annual Global Survey. Each year, our...
-
Project Recovery shipments reaching those in need
Shipments of factor VIII manufactured as part of Project Recovery have started arriving at treatment centres around the world. These are the first deliveries in...
